Price (delayed)
$39.51
Market cap
$2.35B
P/E Ratio
13.67
Dividend/share
N/A
EPS
$2.89
Enterprise value
$2.23B
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2
There are no recent dividends present for PTGX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.